In memory of the late Hilary Hoskin and in thanks to her trust dedicated to young people like her Grandson, Saul Catlin. The exon skipping project is led by Professor Matthew Wood’s team at the University of Oxford and specifically on Peptide platform technology for enhanced oligonucleotide delivery (PepGen).

The PepGen project aims to develop the next generation of short peptides that attach to antisense oligonucleotides that may improve their delivery to muscle. This will drive forward the development of second generation exon skipping therapies for Duchenne muscular dystrophy. The award will fund the screening of new variants of the delivery in order to progress these potential new compounds into clinical trial as soon as possible.

Professor Matthew Wood says, We’re delighted to receive this award from Action Duchenne. The award will help us to accelerate the development of peptide technology that improves the delivery of antisense oligonucleotides for exon skipping and make a real impact on the treatment of DMD“.

Janet Hoskin, Founder of Action Duchenne says “We are so pleased that our Mum’s legacy, The Hilary Hoskin Trust, will be funding research that will improve the delivery of exon-skipping drugs to treat Duchenne muscular dystrophy. These are exciting times in the search for genetic treatments; particularly in the light of the FDA’s decision on Dys51 (eteplirsen) and we hope to see more and more options available to those living with Duchenne.  Our Mum would be incredibly proud of the way her grandson gets on with life,  and we hope that treatments from new biotech start up companies, such as PepGen, will enable him and many others to live longer lives and achieve their aspirations.”